BR112022002122A2 - Composição de mascaramento de sabor dispersível oralmente de hemibromidrato de vortioxetina, método para preparação da composição de mascaramento de sabor dispersível oralmente, e método para tratamento de um transtorno de depressão em um indivíduo - Google Patents
Composição de mascaramento de sabor dispersível oralmente de hemibromidrato de vortioxetina, método para preparação da composição de mascaramento de sabor dispersível oralmente, e método para tratamento de um transtorno de depressão em um indivíduoInfo
- Publication number
- BR112022002122A2 BR112022002122A2 BR112022002122A BR112022002122A BR112022002122A2 BR 112022002122 A2 BR112022002122 A2 BR 112022002122A2 BR 112022002122 A BR112022002122 A BR 112022002122A BR 112022002122 A BR112022002122 A BR 112022002122A BR 112022002122 A2 BR112022002122 A2 BR 112022002122A2
- Authority
- BR
- Brazil
- Prior art keywords
- taste masking
- masking composition
- orally dispersible
- vortioxetine
- hemihydrobromide
- Prior art date
Links
- 230000000873 masking effect Effects 0.000 title abstract 4
- 208000020401 Depressive disease Diseases 0.000 title 1
- YQNWZWMKLDQSAC-UHFFFAOYSA-N vortioxetine Chemical group CC1=CC(C)=CC=C1SC1=CC=CC=C1N1CCNCC1 YQNWZWMKLDQSAC-UHFFFAOYSA-N 0.000 title 1
- 229960002263 vortioxetine Drugs 0.000 title 1
- 239000007931 coated granule Substances 0.000 abstract 1
- 239000007962 solid dispersion Substances 0.000 abstract 1
- 239000008247 solid mixture Substances 0.000 abstract 1
- 229960004030 vortioxetine hydrobromide Drugs 0.000 abstract 1
- VNGRUFUIHGGOOM-UHFFFAOYSA-N vortioxetine hydrobromide Chemical compound Br.CC1=CC(C)=CC=C1SC1=CC=CC=C1N1CCNCC1 VNGRUFUIHGGOOM-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
trata-se de um grânulo revestido, uma dispersão sólida, uma composição e uma preparação para mascaramento de sabor oral que melhoram o efeito de mascaramento de sabor do bromidrato de vortioxetina e melhoram a aderência e a adesão do paciente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910571194 | 2019-09-04 | ||
PCT/CN2020/113341 WO2021043227A1 (zh) | 2019-09-04 | 2020-09-03 | 用于口腔掩味的含氢溴酸沃替西汀的包衣颗粒、固体分散体和制剂 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022002122A2 true BR112022002122A2 (pt) | 2022-04-19 |
Family
ID=74736746
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022002122A BR112022002122A2 (pt) | 2019-09-04 | 2020-09-03 | Composição de mascaramento de sabor dispersível oralmente de hemibromidrato de vortioxetina, método para preparação da composição de mascaramento de sabor dispersível oralmente, e método para tratamento de um transtorno de depressão em um indivíduo |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220249466A1 (pt) |
EP (1) | EP4026539A4 (pt) |
JP (3) | JP2022540249A (pt) |
KR (1) | KR20220061952A (pt) |
CN (3) | CN112438979B (pt) |
AU (1) | AU2020343816A1 (pt) |
BR (1) | BR112022002122A2 (pt) |
CA (1) | CA3146024A1 (pt) |
MX (1) | MX2022002444A (pt) |
WO (1) | WO2021043227A1 (pt) |
ZA (1) | ZA202200542B (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113520998A (zh) * | 2021-07-26 | 2021-10-22 | 北京丰科睿泰医药科技有限公司 | 一种伏硫西汀口服滴剂及其制备方法 |
CN116650487A (zh) * | 2022-06-27 | 2023-08-29 | 中国人民解放军军事科学院军事医学研究院 | 一种氢溴酸伏硫西汀药物组合物及其制备方法和其应用 |
GB2622880A (en) | 2022-09-30 | 2024-04-03 | Alkaloid Ad Skopje | Palatable orodispersible formulation of vortioxetine |
CN115869290B (zh) * | 2022-12-07 | 2024-05-28 | 杭州成邦医药科技有限公司 | 一种西替利嗪口腔膜剂及其制备方法 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2821745B1 (fr) * | 2001-03-09 | 2004-07-02 | Ethypharm Lab Prod Ethiques | Granules et granules enrobes au gout masque |
JP2006514968A (ja) * | 2003-04-02 | 2006-05-18 | プリヴァ−イストラジヴァンジェ・イ・ラズヴォイ・ディー・オー・オー | 低減された苦味を有する製薬組成物 |
ES2379200T5 (es) | 2006-06-16 | 2021-10-20 | H Lundbeck As | Bromhidrato de 1-[2-(2,4-Dimetilfenilsulfanil)fenil]piperazina como compuesto con recaptación de serotonina combinada con actividad 5-HT3 y 5-HT1A para el tratamiento del deterioro cognitivo |
US20160200698A1 (en) * | 2013-09-12 | 2016-07-14 | Hangzhou Pushai Pharmaceutical Technology Co., Ltd | Vortioxetine salt and crystal thereof, their preparation method, pharmaceutical compositions and usage |
WO2015044963A1 (en) * | 2013-09-30 | 2015-04-02 | Cadila Healthcare Limited | An amorphous vortioxetine and salts thereof |
CN103989650A (zh) * | 2014-06-13 | 2014-08-20 | 李雪梅 | 一种口腔崩解药物组合物及其制备方法 |
CN104586756A (zh) * | 2015-01-05 | 2015-05-06 | 万特制药(海南)有限公司 | 一种含沃替西汀的口服溶液及其制备方法 |
CN105030713A (zh) * | 2015-06-27 | 2015-11-11 | 万特制药(海南)有限公司 | 一种沃替西汀缓释片及其制备方法 |
CN105111167A (zh) * | 2015-08-06 | 2015-12-02 | 华南理工大学 | 一种沃替西汀半盐酸盐及其制备方法和药物组合物 |
CN107638425A (zh) * | 2016-07-21 | 2018-01-30 | 常州爱诺新睿医药技术有限公司 | 一种新的含无定型沃替西汀氢溴酸盐的药用组合物及其制备方法 |
CN106491604A (zh) * | 2015-09-07 | 2017-03-15 | 常州方楠医药技术有限公司 | 一种无定型沃替西汀或其盐与药用辅料的组合物及其制备方法 |
EP3184104B1 (en) * | 2015-12-23 | 2018-09-12 | Hexal AG | Pharmaceutical composition of vortioxetine hydrobromide comprising vortioxetine hydrobromide in a polyethylene oxide matrix |
CN105534933A (zh) * | 2016-01-19 | 2016-05-04 | 美吉斯制药(厦门)有限公司 | 一种沃替西汀口腔崩解片及其制备方法 |
CA3016809C (en) * | 2016-03-14 | 2024-03-12 | Santen Pharmaceutical Co., Ltd. | Antiseptic agent comprising meglumine or salt thereof |
WO2018065348A1 (en) * | 2016-10-05 | 2018-04-12 | Hexal Ag | Novel enteric-coated tablet comprising vortioxetine |
CN108069925A (zh) * | 2016-11-16 | 2018-05-25 | 浙江京新药业股份有限公司 | 沃替西汀氢溴酸盐无水晶型i及其制备方法和应用 |
CN108498459A (zh) * | 2017-02-23 | 2018-09-07 | 北京阜康仁生物制药科技有限公司 | 一种包含氢溴酸沃替西汀的药物组合物及其制备方法 |
CN107412183A (zh) * | 2017-04-17 | 2017-12-01 | 深圳市泛谷药业股份有限公司 | 一种氢溴酸沃替西汀片及其制备方法 |
CN109589314A (zh) * | 2017-10-01 | 2019-04-09 | 万全万特制药(厦门)有限公司 | 含有氢溴酸沃替西汀口崩片的制备方法 |
-
2020
- 2020-09-03 CA CA3146024A patent/CA3146024A1/en active Pending
- 2020-09-03 CN CN202010915483.3A patent/CN112438979B/zh active Active
- 2020-09-03 BR BR112022002122A patent/BR112022002122A2/pt unknown
- 2020-09-03 US US17/617,805 patent/US20220249466A1/en active Pending
- 2020-09-03 CN CN202210459260.XA patent/CN114931579A/zh active Pending
- 2020-09-03 JP JP2022502045A patent/JP2022540249A/ja active Pending
- 2020-09-03 CN CN202210477756.XA patent/CN114796222B/zh active Active
- 2020-09-03 EP EP20861501.3A patent/EP4026539A4/en active Pending
- 2020-09-03 WO PCT/CN2020/113341 patent/WO2021043227A1/zh active Application Filing
- 2020-09-03 KR KR1020227004281A patent/KR20220061952A/ko active Search and Examination
- 2020-09-03 AU AU2020343816A patent/AU2020343816A1/en active Pending
- 2020-09-03 MX MX2022002444A patent/MX2022002444A/es unknown
-
2022
- 2022-01-11 ZA ZA2022/00542A patent/ZA202200542B/en unknown
-
2023
- 2023-04-10 JP JP2023063529A patent/JP2023089096A/ja active Pending
- 2023-10-19 JP JP2023180274A patent/JP2024010032A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20220061952A (ko) | 2022-05-13 |
ZA202200542B (en) | 2023-11-29 |
MX2022002444A (es) | 2022-03-22 |
CA3146024A1 (en) | 2021-03-11 |
EP4026539A4 (en) | 2023-07-19 |
CN114796222B (zh) | 2024-03-29 |
AU2020343816A1 (en) | 2022-02-24 |
EP4026539A1 (en) | 2022-07-13 |
CN114931579A (zh) | 2022-08-23 |
JP2023089096A (ja) | 2023-06-27 |
US20220249466A1 (en) | 2022-08-11 |
JP2022540249A (ja) | 2022-09-14 |
WO2021043227A1 (zh) | 2021-03-11 |
CN112438979B (zh) | 2022-05-27 |
CN112438979A (zh) | 2021-03-05 |
CN114796222A (zh) | 2022-07-29 |
JP2024010032A (ja) | 2024-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022002122A2 (pt) | Composição de mascaramento de sabor dispersível oralmente de hemibromidrato de vortioxetina, método para preparação da composição de mascaramento de sabor dispersível oralmente, e método para tratamento de um transtorno de depressão em um indivíduo | |
CL2019000935A1 (es) | Composición farmacéutica, métodos para tratamiento y usos de la misma. | |
BR112017017448A2 (pt) | métodos e composições para o tratamento de doença do olho ressecado e outros distúrbios do olho | |
BR112018076114A2 (pt) | composições tópicas de apremilast | |
MA40240A (fr) | Composés hétéroaryle d'inhibition de la kinase | |
BR112021019262A2 (pt) | Uso de ciclo-his-pro (chp) para prevenir, atenuar ou tratar fibrose | |
BR112018007560A2 (pt) | composição cosmética tendo bactérias probióticas | |
WO2020086747A3 (en) | Ssao inhibitors and uses thereof | |
MX2021016109A (es) | Metodos y composiciones particularmente para el tratamiento del trastorno por deficit de atencion. | |
BR112018008186A2 (pt) | métodos que utilizam proteína de soro de leite para melhorar ou manter a qualidade muscular | |
BR112021016296A2 (pt) | Formulações tópicas de rapamicina e seu uso em tratamento de angiofibromas faciais e outros distúrbios de pele | |
TR201908938T4 (tr) | Ağız, boğaz ve solunum yolu rahatsızlıklarının tedavisi için formülasyonlar. | |
BR112019005985A2 (pt) | composições de combinação compreendendo agonistas de fxr para tratar ou prevenir uma doença ou distúrbio fibrótico, cirrótico | |
EP3982994A4 (en) | COMPOSITIONS AND METHODS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS | |
BR112021017550A2 (pt) | Métodos de tratamento da amiloidose al | |
EP3968916A4 (en) | GLAND TREATMENT DEVICES AND METHODS OF TREATING DRY EYE DISEASE | |
EP3897181A4 (en) | ORAL EGG IMMUNOTHERAPY FORMULATIONS, MANUFACTURING METHODS AND TREATMENTS FOR EGG ALLERGIES | |
CR20210514A (es) | USO DE REBOXETINA PARA EL TRATAMIENTO DE NARCOLEPSIA (Divisional 2021-0183) | |
IL299916A (en) | Prenatal dosage forms, administration methods and their kits | |
BR112019000706A8 (pt) | Agente de estímulo do receptor 1b de 5-hidroxitriptamina para reparo de pele e/ou cabelo | |
PL423673A1 (pl) | Kompozycja do podawania doustnego, zastosowanie kompozycji w zapobieganiu i leczeniu mucositis oraz sposób leczenia mucositis | |
EP3765062A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF POLYGLUCOUS DISORDERS | |
EP3777849A4 (en) | PHARMACEUTICAL COMPOSITION, COMPRISING POLMACOXIB AND PREGABALIN, FOR THE TREATMENT OF PAIN | |
MX2019005818A (es) | Preparacion cosmetica de viscosidad mejorada para tratamiento de fibras queratinicas, metodo para incrementar la viscosidad de una preparacion cosmetica, uso de ingredientes modificadores de la viscosidad y metodo de tratamiento de fibras queratinicas. | |
CL2021003442A1 (es) | Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122023014426-0 PROTOCOLO 870230063013 EM 18/07/2023 17:24. |